CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD)

CRISPR Therapeutics Trading Halted Today; FDA Advisory Committee to Review Biologics License Application (BLA) for Exagamglogene Autotemcel (exa-cel) in Sickle Cell Disease (SCD) ZUG, Switzerland and BOSTON , Oct. 31, 2023 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that NASDAQ has halted trading of the Company’s common stock. The U.S. Food and Drug Administration’s (FDA) Cellular, Tissue, and Gene Therapies Advisory Committee is meeting today to review the Biologics License Application (BLA) for exagamglogene autotemcel (exa-cel) for the treatment of sickle cell disease (SCD) in people ages 12 and older with recurrent vaso-occlusive crises. The Advisory Committee meeting is scheduled for 9:00 AM ET . The briefing materials can be found on the FDA website HERE . The Prescription Drug User Fee Act date for completion of the review of the BLA for exa-cel for SCD is December 8, 2023 . About CRISPR Therapeutics CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and cardiometabolic diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic partnerships with leading companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland , with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Boston, Massachusetts and San Francisco, California , and business offices in London, United Kingdom . For more information, please visit www.crisprtx.com . CRISPR THERAPEUTICS ® standard character mark and design logo are trademarks and registered trademarks of CRISPR Therapeutics AG . All other trademarks and registered trademarks are the property of their respective owners. Investor Contact: Susan Kim +1-617-307-7503 [email protected] Media Contact: Rachel Eides +1-617-315-4493 [email protected] Source: CRISPR Therapeutics AG © 2026 CRISPR Therapeutics. All rights reserved. CRISPR THERAPEUTICS® standard character mark and design logo are registered trademarks of CRISPR Therapeutics AG. Solely for convenience, trademarks, service marks, and trade names referred to on this website may appear without the ® or ™ symbols, and any such omission is not intended to indicate waiver of any such rights. For more information regarding our programs outside of the United States, please contact us here

The release as fetched from its publisher. crisprtx.com ↗